


Only Test With Actionable Results for Short-Term ADT

Also Providing Insights for Active Surveillance




Where does the ArteraAI Prostate Test fit in the patient journey?



The test is designed to support clinical decision-making through **risk stratification**, suitability for **active surveillance**,^a and prediction of **ST-ADT benefit**^b for patient with localized prostate cancer.

How can the prognostic and predictive results be used to guide treatment decisions?



^aFor patients with NCCN very low-, low-, or favorable-intermediate risk.

^bFor patients with NCCN intermediate-risk.¹

Multimodal artificial intelligence (ArteraAI Prostate Test) is the only predictive ST-ADT tool recommended in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer¹



REIMBURSABLE BY MEDICARE

The Centers for Medicare & Medicaid Services have established a payment rate



DOES NOT CONSUME TISSUE

Analysis uses image data from existing biopsy slides with no additional staining or preparation required



RAPID TURNAROUND

Results can be shared within 2-3 days after receipt of the patient's specimen by our CLIA lab



DEVELOPED FROM LARGE DATASETS

Trained and validated using data from thousands of patients enrolled in multiple NRG/RTOG phase 3 randomized trials with up to 20 years of follow-up^{2,4}



REPRESENTS DIVERSE POPULATIONS

Consistent prognostic performance between African American and non-African American men⁵

"I think that this test is really transformative.
We have never had any predictive biomarkers to use in clinical practice until now.
We have been talking about this and wanting a tool like this for decades."

- Daniel E. Spratt, MD, University Hospitals Seidman Cancer Center, Case Western Reserve University



Sample Test Report



Test Guide

The ArteraAI Prostate Test is a Laboratory Developed Test that is now clinically available through a single CLIA-certified laboratory in Jacksonville, FL. This test has not been cleared or approved by the U.S. Food and Drug Administration.

AI, artificial intelligence; CLIA, Clinical Laboratory Improvement Amendments; NCCN, National Comprehensive Cancer Network; ST-ADT, short-term androgen deprivation therapy.

1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer V.4.2024. ©National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed June 4, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way. 2. Esteva A, et al. *NPJ Digit Med.* 2022;5(1):71. 3. Data on File. Artera, 2023. 4. Spratt DE, et al. *NEJM Evidence.* 2023;2(8). 5. Roach M, et al. Presented at: ASCO. 2022: Abstract 108.



artera.ai
Customer Service can be reached at 1-650-239-7018
Artera is located at 108 First Street, Los Altos, CA 94022, USA
Artera© All Rights Reserved. 7/24.

